THE Therapeutic Goods
Administration has issued a
statement reaffirming that Rotarix
and RotaTeq are both suitable for
use for the prevention of infection
with rotavirus, including in babies
aged 2-6 months.
The move follows a similar
statement by the US Food and
Drug Administration (PD
yesterday), with authorities looking
into the vaccines after
manufacturers confirmed the
presence of DNA fragments from
porcine circovirus type 1 (PCV1) in
some batches.
The TGA said it had convened an
expert panel of paediatricians,
immunologists and vaccine
specialist which had agreed that
the evidence supports the ongoing
use of the vaccines as “strongly in
the public interest.
“Having considered all the relevant scientific information the
TGA has concluded that the
continued use of both vaccines is
strongly supported by the weight of
current evidence and the long
history of safe use of the products,”
the TGA said.The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.